New diabetes pill shows promise in year-long safety trial
NCT ID NCT02314637
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the long-term safety and blood sugar control of the drug MP-513 (Teneligliptin) in 240 Japanese adults with type 2 diabetes. Some participants took MP-513 alone, while others took it together with another diabetes medicine called glimepiride. The study lasted 52 weeks and tracked side effects and changes in blood sugar levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Reserch site
Shikoku, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Can a spice and a mindset shift ease diabetic nerve pain?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Could a peptide injection help rebuild Insulin-Making cells?
- A pill for diabetes? new oral drug aims to rival injections